Clinical Study

Safety Study Of Study Drug 4 Given As A Single Intratympanic Injection In Subjects With Unilateral Meniere’S Disease

Posted Date: Jan 19, 2017

  • Investigator: Ravi Samy
  • Co-Investigator: Ravi Samy
  • Specialties: Otolaryngology, Audiology
  • Type of Study: Drug

The purpose of this study is to test the effectiveness and safety of OTO-104 compared to placebo in subjects with Meniere’s disease. A placebo is an inactive substance that looks like OTO-104 but does not contain active drug.OTO-104 contains an active ingredient, called dexamethasone, which is a commonly used corticosteroid that has been prescribed by doctors for several decades. When injected into the body at room temperature, OTO-104 turns into a gel and remains in the place it was injected for several weeks. The substance that turns OTO-104 into a gel is called poloxamer 407.


You Are Being Asked To Participate In A Research Study Of An Investigational Drug, Called Oto-104, For The Symptoms Of Meniere’S Disease. An Investigational Drug Is One That Is Not Approved By The United States Food And Drug Administration (Fda).


Meniere’S Disease, Vertigo, Null, Null, Null

For More Information:

Becky Reinert

  • Search Clinical Studies

  • Research in the News

    Enhanced Recovery Program for Colorectal Surgery Patients Reduces Costs

    A standardized protocol for managing patients for the duration of colorectaloperations not only improved clinical outcomes, but also it significantlyreduced hospital costs.